vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $20.4M, roughly 1.7× Sight Sciences, Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -20.4%, a 18.6% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -3.2%). Sight Sciences, Inc. produced more free cash flow last quarter ($-2.0M vs $-2.4M). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -3.5%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CLFD vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $20.4M |
| Net Profit | $-614.0K | $-4.2M |
| Gross Margin | 33.2% | 87.3% |
| Operating Margin | -5.3% | -18.0% |
| Net Margin | -1.8% | -20.4% |
| Revenue YoY | -3.2% | 6.9% |
| Net Profit YoY | 67.8% | 64.9% |
| EPS (diluted) | $-0.04 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $20.4M | ||
| Q3 25 | $23.4M | $19.9M | ||
| Q2 25 | $49.9M | $19.6M | ||
| Q1 25 | $47.2M | $17.5M | ||
| Q4 24 | $29.7M | $19.1M | ||
| Q3 24 | $5.6M | $20.2M | ||
| Q2 24 | $48.8M | $21.4M | ||
| Q1 24 | $36.9M | $19.3M |
| Q4 25 | $-614.0K | $-4.2M | ||
| Q3 25 | $-9.1M | $-8.2M | ||
| Q2 25 | $1.6M | $-11.9M | ||
| Q1 25 | $1.3M | $-14.2M | ||
| Q4 24 | $-1.9M | $-11.8M | ||
| Q3 24 | — | $-11.1M | ||
| Q2 24 | $-447.0K | $-12.3M | ||
| Q1 24 | $-5.9M | $-16.3M |
| Q4 25 | 33.2% | 87.3% | ||
| Q3 25 | 53.2% | 86.4% | ||
| Q2 25 | 30.5% | 84.8% | ||
| Q1 25 | 30.1% | 86.2% | ||
| Q4 24 | 29.2% | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | 21.9% | 85.8% | ||
| Q1 24 | 7.7% | 85.5% |
| Q4 25 | -5.3% | -18.0% | ||
| Q3 25 | 10.3% | -39.7% | ||
| Q2 25 | 3.0% | -59.6% | ||
| Q1 25 | 0.6% | -79.2% | ||
| Q4 24 | -6.9% | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | -4.7% | -59.2% | ||
| Q1 24 | -26.4% | -76.4% |
| Q4 25 | -1.8% | -20.4% | ||
| Q3 25 | -38.8% | -41.0% | ||
| Q2 25 | 3.2% | -61.0% | ||
| Q1 25 | 2.8% | -80.8% | ||
| Q4 24 | -6.4% | -62.1% | ||
| Q3 24 | — | -54.9% | ||
| Q2 24 | -0.9% | -57.7% | ||
| Q1 24 | -16.0% | -84.4% |
| Q4 25 | $-0.04 | $-0.07 | ||
| Q3 25 | $-0.65 | $-0.16 | ||
| Q2 25 | $0.11 | $-0.23 | ||
| Q1 25 | $0.09 | $-0.28 | ||
| Q4 24 | $-0.13 | $-0.23 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | $-0.04 | $-0.25 | ||
| Q1 24 | $-0.40 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $249.7M | $63.9M |
| Total Assets | $268.1M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $92.0M | ||
| Q3 25 | $106.0M | $92.4M | ||
| Q2 25 | $117.2M | $101.5M | ||
| Q1 25 | $112.0M | $108.8M | ||
| Q4 24 | $113.0M | $120.4M | ||
| Q3 24 | $129.0M | $118.6M | ||
| Q2 24 | $123.8M | $118.2M | ||
| Q1 24 | $142.9M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | $2.2M | $37.1M | ||
| Q2 24 | $2.1M | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $249.7M | $63.9M | ||
| Q3 25 | $256.2M | $64.3M | ||
| Q2 25 | $264.5M | $70.0M | ||
| Q1 25 | $265.9M | $77.6M | ||
| Q4 24 | $267.4M | $87.5M | ||
| Q3 24 | $275.8M | $95.0M | ||
| Q2 24 | $274.6M | $101.6M | ||
| Q1 24 | $279.2M | $109.2M |
| Q4 25 | $268.1M | $115.3M | ||
| Q3 25 | $306.2M | $116.3M | ||
| Q2 25 | $314.7M | $122.0M | ||
| Q1 25 | $310.9M | $129.7M | ||
| Q4 24 | $303.2M | $142.8M | ||
| Q3 24 | $315.3M | $143.6M | ||
| Q2 24 | $318.1M | $149.7M | ||
| Q1 24 | $315.4M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | 0.01× | 0.39× | ||
| Q2 24 | 0.01× | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-1.8M |
| Free Cash FlowOCF − Capex | $-2.4M | $-2.0M |
| FCF MarginFCF / Revenue | -7.1% | -9.7% |
| Capex IntensityCapex / Revenue | 2.9% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $-1.8M | ||
| Q3 25 | — | $-8.7M | ||
| Q2 25 | $7.9M | $-7.5M | ||
| Q1 25 | $3.0M | $-11.6M | ||
| Q4 24 | $7.2M | $-3.5M | ||
| Q3 24 | $22.2M | $362.0K | ||
| Q2 24 | $4.0M | $-9.5M | ||
| Q1 24 | $-5.7M | $-9.8M |
| Q4 25 | $-2.4M | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | $7.5M | $-7.8M | ||
| Q1 25 | $654.0K | — | ||
| Q4 24 | $5.1M | $-3.6M | ||
| Q3 24 | $18.2M | $311.0K | ||
| Q2 24 | $2.8M | $-9.5M | ||
| Q1 24 | $-7.7M | $-9.9M |
| Q4 25 | -7.1% | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | 15.1% | -39.6% | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 17.1% | -18.9% | ||
| Q3 24 | 323.0% | 1.5% | ||
| Q2 24 | 5.8% | -44.7% | ||
| Q1 24 | -20.8% | -51.4% |
| Q4 25 | 2.9% | 0.8% | ||
| Q3 25 | 2.0% | 0.9% | ||
| Q2 25 | 0.8% | 1.1% | ||
| Q1 25 | 5.1% | 0.0% | ||
| Q4 24 | 7.0% | 0.7% | ||
| Q3 24 | 71.4% | 0.3% | ||
| Q2 24 | 2.5% | 0.4% | ||
| Q1 24 | 5.3% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
